ArticleEJHaem2026
Real-World Treatment Patterns, Burden of Illness, and Survival of Autologous Stem Cell Transplant-Ineligible Patients With Mantle Cell Lymphoma in Ontario, Canada.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Since the approval of ibrutinib in 2016 in Canada for relapsed or refractory (R/R) mantle cell lymphoma (MCL), there has been limited evidence characterizing treatment patterns, burden of illness, and survival in Canadian patients ineligible for autologous stem cell transplant (ASCT). This is the first study in Ontario reporting real-world treatment patterns and clinical outcomes of elderly patients with MCL who are transplant-ineligible in 1L and R/R settings. Methods: The aim of this study was to characterize the real-world use and outcomes of patients with MCL who were ≥ 65 years old and transplant-ineligible in first-line (1L) and R/R settings between 2013 and 2021 using administrative databases in Ontario, Canada. Incidence of MCL, treatment patterns, and overall survival (OS) were assessed. Results: The study cohort consisted of 754 patients (follow-up: 36.1 months, median age: 76 [IQR: 71-82], 71.1% male). Most patients received bendamustine and rituximab in 1L (76.7%) and ibrutinib in second-line (2L; 73.2%). Mortality rates following 1L and 2L therapy were 39.3% and 68.5%, respectively. Duration of therapy in 1L and 2L treatment was 4.70 and 2.14 months, respectively. Median OS decreased with subsequent lines of therapy (1L: 3.51 years; 2L: 0.60 years; third-line: 0.43 years). Conclusion: This study characterized the treatment patterns, rwOS, and TTNT-D of MCL patients in Ontario, Canada. Poor real-world clinical outcomes support the need for additional 1L and R/R therapies for MCL management for an ASCT-ineligible population. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.